BioMarin Pharmaceutical Inc
BMRN
View Detailed Chart
55.040USD
+0.670+1.23%
Market hours （ET）Quotes delayed by 15 min
10.57BMarket Cap
16.08P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.23%
5 Days
+0.99%
1 Month
-4.34%
6 Months
-23.07%
Year to Date
-16.26%
1 Year
-21.98%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
29
analysts
Buy
Current Rating
96.802
Target Price
+79.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36.16% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 201.54.
Undervalued
The company’s latest PE is 15.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 195.10M shares, decreasing 7.58% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.91M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Ticker SymbolBMRN
CompanyBioMarin Pharmaceutical Inc
CEOMr. Alexander Hardy
Websitehttps://www.biomarin.com/
Related Instruments
+0.10%
-1.47%
+0.30%
-0.94%
+0.21%
+6.08%
+0.37%
+0.35%
+1.01%
+0.44%
+1.41%
+0.03%
-1.07%
-0.07%
-0.19%
-1.54%
-0.02%
+0.26%
+2.01%
-1.15%
